
Researchers have discovered that canagliflozin, a drug commonly used to treat type 2 diabetes, may also effectively treat autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Canagliflozin targets T-cells, which play a vital role in the immune system. The study found that canagliflozin reduces T-cell activation, indicating its potential for treating T-cell-driven autoimmunity. The drug's existing safety profile and widespread use in diabetes treatment suggest it could quickly advance to clinical trials for autoimmune disorders.
Like
Save
Share